NICHOLAS LEMMING: Open Payments
NPI 1427033562 · SEYMOUR, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$876 in 42 payments from 12 companies in 2025. Trend: 2023 $1,006 · 2024 $1,044 · 2025 $876
Food & beverage: $838Education: $38
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $191 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $151 |
| GlaxoSmithKline, LLC. | 6 | $115 |
| ABBVIE INC. | 5 | $104 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $95 |
| Novo Nordisk Inc | 5 | $79 |
| Lilly USA, LLC | 3 | $44 |
| Neurocrine BioSciences, Inc. | 1 | $26 |
| Abbott Laboratories | 1 | $20 |
| PFIZER INC. | 1 | $19 |
Products named: CAPLYTA, TRELEGY ELLIPTA, FARXIGA, JARDIANCE, VRAYLAR, Wegovy, BREZTRI, BEVESPI AEROSPHERE.
Industry payments across IN — which companies pay providers there.
